Rezolute (RZLT) Net Income towards Common Stockholders (2012 - 2026)
Rezolute (RZLT) posted Net Income towards Common Stockholders of -$20.9 million for Q1 2026, up 17.2% sequentially from -$25.3 million in Q4 2025, and up 13.68% YoY from -$18.4 million in Q1 2025.
Powered by 
Analysis
Rezolute (RZLT) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Rezolute has reported Net Income towards Common Stockholders for 15 years, with the latest figure at -$20.9 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 13.68% year-over-year to -$20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$163.3 million (down 43.66% YoY) and the FY2025 annual result came in at -$74.4 million, down 8.7% from the prior year.
- Net Income towards Common Stockholders climbed to -$20.9 million in Q1 2026 per RZLT's latest filing, from -$25.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$10.0 million in Q3 2022 and troughed at -$92.5 million in Q3 2025.
- A 5-year average of -$23.7 million and a median of -$19.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 27.66% in 2025, down 158.47% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$14.1 million in 2022, then fell by 0.68% to -$14.2 million in 2023, then tumbled by 145.39% to -$34.9 million in 2024, then climbed by 27.66% to -$25.3 million in 2025, then increased by 17.2% to -$20.9 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$20.9 million, -$25.3 million, and -$92.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rezolute | 476.50 Mn | 476.50 Mn | - | -16.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -16.17 Mn |
| Dec 31, 2025 | -22.77 Mn |
| Sep 30, 2025 | -18.14 Mn |
| Jun 30, 2025 | -24.41 Mn |
| Mar 31, 2025 | -18.91 Mn |
| Dec 31, 2024 | -15.74 Mn |
| Sep 30, 2024 | -15.36 Mn |
| Jun 30, 2024 | -22.06 Mn |
| Mar 31, 2024 | -15.09 Mn |
| Dec 31, 2023 | -13.89 Mn |
| Sep 30, 2023 | -14.51 Mn |
| Jun 30, 2023 | -12.76 Mn |
| Mar 31, 2023 | -15.66 Mn |
| Dec 31, 2022 | -13.54 Mn |
| Sep 30, 2022 | -9.82 Mn |
| Jun 30, 2022 | -11.78 Mn |
| Mar 31, 2022 | -11.20 Mn |
| Dec 31, 2021 | -12.59 Mn |
| Sep 30, 2021 | -8.08 Mn |
| Jun 30, 2021 | -7.07 Mn |